These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
272 related articles for article (PubMed ID: 25131634)
21. Effects of Maternal Choline Supplementation on the Septohippocampal Cholinergic System in the Ts65Dn Mouse Model of Down Syndrome. Kelley CM; Ash JA; Powers BE; Velazquez R; Alldred MJ; Ikonomovic MD; Ginsberg SD; Strupp BJ; Mufson EJ Curr Alzheimer Res; 2016; 13(1):84-96. PubMed ID: 26391045 [TBL] [Abstract][Full Text] [Related]
22. A noradrenergic lesion exacerbates neurodegeneration in a Down syndrome mouse model. Lockrow J; Boger H; Gerhardt G; Aston-Jones G; Bachman D; Granholm AC J Alzheimers Dis; 2011; 23(3):471-89. PubMed ID: 21098982 [TBL] [Abstract][Full Text] [Related]
23. Microarray analysis of hippocampal CA1 neurons implicates early endosomal dysfunction during Alzheimer's disease progression. Ginsberg SD; Alldred MJ; Counts SE; Cataldo AM; Neve RL; Jiang Y; Wuu J; Chao MV; Mufson EJ; Nixon RA; Che S Biol Psychiatry; 2010 Nov; 68(10):885-93. PubMed ID: 20655510 [TBL] [Abstract][Full Text] [Related]
24. Increased Sparsity of Hippocampal CA1 Neuronal Ensembles in a Mouse Model of Down Syndrome Assayed by Arc Expression. Smith-Hicks CL; Cai P; Savonenko AV; Reeves RH; Worley PF Front Neural Circuits; 2017; 11():6. PubMed ID: 28217086 [TBL] [Abstract][Full Text] [Related]
25. Temporal and brain region-specific elevations of soluble Amyloid-β Tallino S; Winslow W; Bartholomew SK; Velazquez R Aging Cell; 2022 Apr; 21(4):e13590. PubMed ID: 35290711 [TBL] [Abstract][Full Text] [Related]
26. Oxidative Phosphorylation Is Dysregulated Within the Basocortical Circuit in a 6-month old Mouse Model of Down Syndrome and Alzheimer's Disease. Alldred MJ; Lee SH; Stutzmann GE; Ginsberg SD Front Aging Neurosci; 2021; 13():707950. PubMed ID: 34489678 [TBL] [Abstract][Full Text] [Related]
27. Synaptic gene dysregulation within hippocampal CA1 pyramidal neurons in mild cognitive impairment. Counts SE; Alldred MJ; Che S; Ginsberg SD; Mufson EJ Neuropharmacology; 2014 Apr; 79():172-9. PubMed ID: 24445080 [TBL] [Abstract][Full Text] [Related]
28. Basal Forebrain Cholinergic Neurons: Linking Down Syndrome and Alzheimer's Disease. Martinez JL; Zammit MD; West NR; Christian BT; Bhattacharyya A Front Aging Neurosci; 2021; 13():703876. PubMed ID: 34322015 [TBL] [Abstract][Full Text] [Related]
29. Early Appearance of Dendritic Alterations in Neocortical Pyramidal Neurons of the Ts65Dn Model of Down Syndrome. Uguagliati B; Stagni F; Emili M; Giacomini A; Russo C; Guidi S; Bartesaghi R Dev Neurosci; 2022; 44(1):23-38. PubMed ID: 34852343 [TBL] [Abstract][Full Text] [Related]
30. Normalizing the gene dosage of Dyrk1A in a mouse model of Down syndrome rescues several Alzheimer's disease phenotypes. García-Cerro S; Rueda N; Vidal V; Lantigua S; Martínez-Cué C Neurobiol Dis; 2017 Oct; 106():76-88. PubMed ID: 28647555 [TBL] [Abstract][Full Text] [Related]
31. Hippocampal hypocellularity in the Ts65Dn mouse originates early in development. Lorenzi HA; Reeves RH Brain Res; 2006 Aug; 1104(1):153-9. PubMed ID: 16828061 [TBL] [Abstract][Full Text] [Related]
32. Glutamatergic transmission aberration: a major cause of behavioral deficits in a murine model of Down's syndrome. Kaur G; Sharma A; Xu W; Gerum S; Alldred MJ; Subbanna S; Basavarajappa BS; Pawlik M; Ohno M; Ginsberg SD; Wilson DA; Guilfoyle DN; Levy E J Neurosci; 2014 Apr; 34(15):5099-106. PubMed ID: 24719089 [TBL] [Abstract][Full Text] [Related]
33. Effects of long-term memantine on memory and neuropathology in Ts65Dn mice, a model for Down syndrome. Lockrow J; Boger H; Bimonte-Nelson H; Granholm AC Behav Brain Res; 2011 Aug; 221(2):610-22. PubMed ID: 20363261 [TBL] [Abstract][Full Text] [Related]
34. Expression profiling of precuneus layer III cathepsin D-immunopositive pyramidal neurons in mild cognitive impairment and Alzheimer's disease: Evidence for neuronal signaling vulnerability. He B; Perez SE; Lee SH; Ginsberg SD; Malek-Ahmadi M; Mufson EJ J Comp Neurol; 2020 Nov; 528(16):2748-2766. PubMed ID: 32323319 [TBL] [Abstract][Full Text] [Related]
35. Developmentally altered inhibition in Ts65Dn, a mouse model of Down syndrome. Mitra A; Blank M; Madison DV Brain Res; 2012 Feb; 1440():1-8. PubMed ID: 22284618 [TBL] [Abstract][Full Text] [Related]
36. Cholinergic Senescence in the Ts65Dn Mouse Model for Down Syndrome. Kirstein M; Cambrils A; Segarra A; Melero A; Varea E Neurochem Res; 2022 Oct; 47(10):3076-3092. PubMed ID: 35767135 [TBL] [Abstract][Full Text] [Related]
37. A flavonoid agonist of the TrkB receptor for BDNF improves hippocampal neurogenesis and hippocampus-dependent memory in the Ts65Dn mouse model of DS. Stagni F; Giacomini A; Guidi S; Emili M; Uguagliati B; Salvalai ME; Bortolotto V; Grilli M; Rimondini R; Bartesaghi R Exp Neurol; 2017 Dec; 298(Pt A):79-96. PubMed ID: 28882412 [TBL] [Abstract][Full Text] [Related]
38. Dysfunctional hippocampal inhibition in the Ts65Dn mouse model of Down syndrome. Best TK; Cramer NP; Chakrabarti L; Haydar TF; Galdzicki Z Exp Neurol; 2012 Feb; 233(2):749-57. PubMed ID: 22178330 [TBL] [Abstract][Full Text] [Related]
39. Pharmacotherapy with fluoxetine restores functional connectivity from the dentate gyrus to field CA3 in the Ts65Dn mouse model of down syndrome. Stagni F; Magistretti J; Guidi S; Ciani E; Mangano C; Calzà L; Bartesaghi R PLoS One; 2013; 8(4):e61689. PubMed ID: 23620781 [TBL] [Abstract][Full Text] [Related]
40. Abnormal APP, cholinergic and cognitive function in Ts65Dn Down's model mice. Seo H; Isacson O Exp Neurol; 2005 Jun; 193(2):469-80. PubMed ID: 15869949 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]